On March 6, 2013 encouraging results from a study involving rheumatoid arthritis medications were published. This study, available in the March 6 issue of the Journal of the American Medical Association, reassured patients who are taking the newest medications. Results concluded from this particular study revealed that these drugs do not appear to raise the[…]
Breaking News: No Heightened Risk of Shingles for Patients Taking Newer Rheumatoid Arthritis Medications
Anti-Inflammatory, Anti-Psoriatic, Drug Research & Development API, Monoclonal Antibodies / mAb Tags: 331731-18-1AdalimumabEtanerceptHumiraRheumatoid ArthritisRituximab Mar 18, 2013
Adalimumab FDA Approved For Moderate to Severe Ulcerative Colitis
FDA Approval News, FDA Approved 2012, Monoclonal Antibodies / mAb Tags: 331731-18-1AdalimumabHumira Sep 28, 2012
On Friday (09-28-12) the FDA announced Adalimumab CAS# 331731-18-1 has been approved to treat moderate to severe ulcerative colitis, for those who are unresponsive to corticosteroids or immunosuppressants. News of the approval comes as the FDA cites the two clinical trials with positive outcomes, involving 908 ulcerative colitis patients. “Results from both studies showed 16.5%[…]
Tofacitinib as a Non Injectable Treatment for Rheumatoid Arthritis
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Immunosuppressant Tags: HumiraNDAPfizerPsoriasis Jan 09, 2012
Pfizer is currently conducting clinical trials for the drug Tofacitinib CAS# 540737-29-9, as a non injectable treatment for Rheumatiod Arthritis, as well as Psoriasis. Tofacitinib is also being investigated as potential treatment for inflammatory bowel disease, a preventative for organ transplant rejection, and other immunological diseases. Both five and ten milligram doses are slated to[…]
Adalimumab sustains clinical remission after 2 years of therapy in Crohn’s disease
Drug Research & Development API, Monoclonal Antibodies / mAb Tags: AdalimumabHumira May 27, 2011
Studies with Adalimumab and a TNF-α blockade shows promising results for Adalimumab therapy for joint pain. Joint pains have inflicted thousands of people worldwide. Age is a non-modifiable risk factor when it comes to degenerative bone disease. However, certain autoimmune joint diseases affect the young population as well. Juvenile idiopathic arthritis, ankylosing spondylitis, rheumatoid arthritis[…]
